Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript

Michael McElhaugh: Yes. Good question, Thomas. That’s kind of a tough question to answer. I think — and the reason I say that is because, of course, we’d love to present our data at EASL. We always love to present our data at EASL. But of course, we have no idea whether any abstracts that we may or may not submit will be accepted. So, it’s hard to guide specifically to a particular conference. But I think you’re kind of thinking about the timing correctly, that that’s probably around the time when either through a conference or through some other mechanism, the data will likely be available.

Thomas Yip: Got it. Thank you again everyone for taking our questions and we’re looking forward to the data readout in the next few months.

Michael McElhaugh: Great. Thank you, Thomas.

Operator: Thank you. Next question comes from the line of Keay Nakae of Chardan. Your line is now open.

Keay Nakae: My questions have been answered. Thanks.

Michael McElhaugh: Thanks Keay.

Operator: Okay. I’m showing no further questions at this time. I would now like to turn it back to management for closing remarks.

Michael McElhaugh: Great. Thank you. And thanks everyone for joining us this morning. We certainly appreciate your continued interest in and support of Arbutus and we look forward to providing updates as we progress the development of our HBV clinical stage assets. Operator, that concludes our call.

Operator: All right. Thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.